123 related articles for article (PubMed ID: 27518624)
1. Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells.
Liu Y
Methods Mol Biol; 2016; 1473():63-70. PubMed ID: 27518624
[TBL] [Abstract][Full Text] [Related]
2. Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells.
Liu Y
Methods Mol Biol; 2022; 2474():39-46. PubMed ID: 35294754
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.
Liu Y; Flynn TJ; Xia M; Wiesenfeld PL; Ferguson MS
Cell Biol Toxicol; 2015 Oct; 31(4-5):221-30. PubMed ID: 26377104
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
5. Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
Rodrigues RM; De Kock J; Doktorova TY; Rogiers V; Vanhaecke T
Methods Mol Biol; 2015; 1250():279-85. PubMed ID: 26272150
[TBL] [Abstract][Full Text] [Related]
6. Interactions of pharmaceuticals and other xenobiotics on hepatic pregnane X receptor and cytochrome P450 3A signaling pathway in rainbow trout (Oncorhynchus mykiss).
Wassmur B; Gräns J; Kling P; Celander MC
Aquat Toxicol; 2010 Oct; 100(1):91-100. PubMed ID: 20719396
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
Li AP
Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
[TBL] [Abstract][Full Text] [Related]
8. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
Aninat C; Piton A; Glaise D; Le Charpentier T; Langouët S; Morel F; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2006 Jan; 34(1):75-83. PubMed ID: 16204462
[TBL] [Abstract][Full Text] [Related]
9. Puromycin-based purification of cells with high expression of the cytochrome P450 CYP3A4 gene from a patient with drug-induced liver injury (DILI).
Miyata S; Saku N; Akiyama S; Javaregowda PK; Ite K; Takashima N; Toyoda M; Yura K; Kimura T; Nishina H; Nakazawa A; Kasahara M; Nonaka H; Kiyono T; Umezawa A
Stem Cell Res Ther; 2022 Jan; 13(1):6. PubMed ID: 35012658
[TBL] [Abstract][Full Text] [Related]
10. The Use of Human Liver Cell Model and Cytochrome P450 Substrate-Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions.
Zakharyants AA; Burmistrova OA; Poloznikov AA
Bull Exp Biol Med; 2017 Feb; 162(4):515-519. PubMed ID: 28243904
[TBL] [Abstract][Full Text] [Related]
11. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα).
Thomas M; Burk O; Klumpp B; Kandel BA; Damm G; Weiss TS; Klein K; Schwab M; Zanger UM
Mol Pharmacol; 2013 Mar; 83(3):709-18. PubMed ID: 23295386
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of expression of cytochrome P450 3A4 in a human liver epithelial cell line in differentiation-inducing conditions.
Yamazaki T; Tokiwa T
Hum Cell; 2021 May; 34(3):750-758. PubMed ID: 33495943
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide.
Hoekstra R; Nibourg GA; van der Hoeven TV; Plomer G; Seppen J; Ackermans MT; Camus S; Kulik W; van Gulik TM; Elferink RP; Chamuleau RA
Drug Metab Dispos; 2013 Mar; 41(3):562-7. PubMed ID: 23238784
[TBL] [Abstract][Full Text] [Related]
16. The HepaRG cell line is suitable for bioartificial liver application.
Hoekstra R; Nibourg GA; van der Hoeven TV; Ackermans MT; Hakvoort TB; van Gulik TM; Lamers WH; Elferink RP; Chamuleau RA
Int J Biochem Cell Biol; 2011 Oct; 43(10):1483-9. PubMed ID: 21726661
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Evaluation of Cytochrome P450 3A4 Inhibition and Hepatotoxicity in HepaRG 3-D Spheroids.
Shin DS; Seo H; Yang JY; Joo J; Im SH; Kim SS; Kim SK; Bae MA
Int J Toxicol; 2018; 37(5):393-403. PubMed ID: 29923436
[TBL] [Abstract][Full Text] [Related]
18. Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes.
Aasa J; Hu Y; Eklund G; Lindgren A; Baranczewski P; Malmquist J; Turek D; Bueters T
Drug Metab Dispos; 2013 Jan; 41(1):159-69. PubMed ID: 23073735
[TBL] [Abstract][Full Text] [Related]
19. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Hardy KD; Wahlin MD; Papageorgiou I; Unadkat JD; Rettie AE; Nelson SD
Drug Metab Dispos; 2014 Jan; 42(1):162-71. PubMed ID: 24191259
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of high-functioning human iPS cell-derived hepatocyte-like cells for pharmaceutical research.
Takayama K; Hagihara Y; Toba Y; Sekiguchi K; Sakurai F; Mizuguchi H
Biomaterials; 2018 Apr; 161():24-32. PubMed ID: 29421559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
